[Clinical evaluation of cefmenoxime in internal medicine, with special reference to infection associated with hematological disorders].
Clinical evaluation of cefmenoxime (CMX, Bestcall) was performed against infections associated with hematological, respiratory tract and other disorders. Clinical effectiveness of CMX against severe infections with hematological disorders including sepsis, pneumonia, pyelitis and so on was 74.4% for good responses and against the respiratory tract infections, 96.2% for good responses was obtained. Neither objective or subjective side effects nor extreme abnormalities in laboratory tests were observed in these patients. It can be concluded, therefore, that CMX is one of the most useful drugs against infectious diseases associated with hematological disorders, respiratory tract and other disorders.
Kawamura
S
S
Sakata
Y
Y
Chiba
Y
Y
Yoshida
Y
Y
Kanazawa
T
T
Kawazu
S
S
Tsuge
M
M
Tanabe
K
K
Nara
H
H
Aizawa
M
M
D001424:Bacterial Infections / Q000188:drug therapy*; D001660:Biliary Tract Diseases / Q000188:drug therapy; D015281:Cefmenoxime; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D007945:Leukemia, Lymphoid / Q000150:complications; D015470:Leukemia, Myeloid, Acute / Q000150:complications; D009503:Neutropenia / Q000188:drug therapy; D011014:Pneumonia / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D015281:Cefmenoxime; D002439:Cefotaxime